On Monday, shares of Delcath Systems, a specialty pharmaceutical company, leaped 8.9% in premarket trading following the announcement of preliminary revenue figures for the fourth quarter and full year that surpassed analysts' expectations.
The company disclosed its preliminary results for the fourth quarter, projecting revenues of $15.1 million, which is significantly higher than the $12.4 million anticipated by the Bloomberg consensus.
Looking ahead, Delcath Systems has also provided preliminary results for the full year of 2024. The company expects to see revenue of $37.2 million, outpacing the forecasted $34.5 million.
This projection indicates that Delcath Systems anticipates continued growth and a strong market position in the upcoming year.
The better-than-expected preliminary figures have sparked a surge in Delcath Systems' stock price, reflecting investor optimism about the company's financial health and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.